Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 33,170 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Crohn Disease, Inflammatory Bowel Disease
Interventions: Recombinant Human Interleukin-11 (rhIL-11); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: Arvada, Colorado • Chapel Hill, North Carolina

Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions: VDPHL01, Placebo; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 41 more

Conditions: Gout, Hyperuricemia
Interventions: SAP-001; Drug
Lead sponsor: Shanton Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Anaheim, California • South Miami, Florida + 3 more

Conditions: Urinary Tract Infections, Urinary Retention Postoperative, Pelvic Organ Prolapse
Interventions: Methenamine Hippurate 1 g tablet, Placebo tablet; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Posttraumatic Stress Disorder
Interventions: Prazosin, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alcohol Abuse, Alcohol Dependence, Heavy Drinking Days
Interventions: Kudzu extract, Placebo, Medical Management; Drug · Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 21 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Pathological Gambling
Interventions: Bupropion, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Acute Schizophrenia
Interventions: Risperidone ISM 75 mg, Risperidone ISM 100 mg, Placebo of Risperidone ISM; Drug
Lead sponsor: Rovi Pharmaceuticals Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Rogers, Arkansas • Cerritos, California • Garden Grove, California + 17 more

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 54
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more

Conditions: Bipolar Disorder
Interventions: Divalproex Sodium ER, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 16 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Depressive Disorder, Major
Interventions: 5 mg BI 1569912, Placebo matching BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 35
States / cities: Bellflower, California • Long Beach, California • Oceanside, California + 31 more

Conditions: Healthy Adults
Interventions: THCv; Dietary Supplement
Lead sponsor: Canopy Growth Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
Interventions: Glutathione, N-Acetylcysteine, Placebo; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Critical Limb Ischemia
Interventions: Ixmyelocel-T, Placebo; Biological · Other
Lead sponsor: Vericel Corporation; Industry
Eligibility: 35 Years to 90 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 86
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone, Placebo, Rivoglitazone; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 70
States / cities: Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 67 more

Conditions: Gout
Interventions: pegloticase; Biological
Lead sponsor: Savient Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 22
States / cities: San Francisco, California • Santa Maria, California • Whittier, California + 19 more

Conditions: Respiratory Syncytial Virus Infection
Interventions: Presatovir, Presatovir placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 9
States / cities: Chicago, Illinois • Annapolis, Maryland • Detroit, Michigan + 6 more

Conditions: Healthy
Interventions: Clopidogrel, Placebo, Omeprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Gingivitis
Interventions: Probiotics; Other
Lead sponsor: Sunstar Americas; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Asthma in the Elderly
Interventions: Choline, Placebo; Dietary Supplement · Other
Lead sponsor: Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Diabetes Mellitus, Type II
Interventions: Placebo, PF-06291874; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 19
States / cities: Anaheim, California • Chula Vista, California • Walnut Creek, California + 13 more

Conditions: Drug Abuse, Intoxication by Drug, Impairment
Interventions: Placebo, THC, CBD, THC + CBD; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diastolic Dysfunction
Interventions: MITOQUINOL MESYLATE then placebo, Placebo, then MITOQUINOL MESYLATE; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Heart Failure, Diabetes
Interventions: Thiamine, Placebo; Drug
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts • Springfield, Massachusetts

Search by objective public record fields.

Study Evaluating rhIL-11 in Active Crohn's Disease

Efficacy and Safety of VDPHL01 in Males With AGA

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

Urinary Track Infection Prevention After Urogynecological Surgery

Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests

Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons

Bupropion in the Treatment of Pathological Gambling

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression

A Study to Test Different Doses of BI 1569912 in People With Depression

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

Study of Rivoglitazone in Type 2 Diabetes Mellitus

Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis

Asthma in the Elderly: A Study of Choline Supplementation

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

Evaluation of Oral THC and CBD in Men and Women

MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women

Thiamine and Acute Decompensated Heart Failure: Pilot Study